The Valley Desk

ArticleEMBO molecular medicinePublished

Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Children’s Hospital of Philadelphia. Affiliation source

Publication record

Type
Article
Venue
EMBO molecular medicine
Published
Subject terms
Humans; Retinoids; Nicotinic Acids; Sulfatases; Drug Evaluation, Preclinical; Oxidoreductases Acting on Sulfur Group Donors; Multiple Sulfatase Deficiency Disease; Bexarotene; Drug screening; Formylglycine-generating Enzyme; Lysosomal Disorder; Sulfatase-modifying Factor 1
PubMed ID
36789546
PubMed Central ID
PMC9994482
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal